Gout Disease Treatment Market - Global Industry Analysis

Gout Disease Treatment Market - by Conditional Stage (Acute Gout and Chronic Gout), Therapeutic (Urate-Lowering Therapies, Inflammatory), Product (Colchicine, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 02-Oct-2020 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-233 Status : Published

According to the report published by Zion Market Research, global demand for gout disease treatment market was valued at approximately USD 3.24 Billion in 2019, and is expected to generate revenue of around USD 9.05 Billion by end of 2026, growing at a CAGR of around 15.8% between 2020 and 2026.

Description

According to the report published by Zion Market Research, global demand for gout disease treatment market was valued at approximately USD 3.24 Billion in 2019, and is expected to generate revenue of around USD 9.05 Billion by end of 2026, growing at a CAGR of around 15.8% between 2020 and 2026.

Global Gout Disease Treatment Market: Overview

Gout is a disease that is caused by frequent attacks of acute inflammatory arthritis. The symptoms of this disease include red and swollen joint, itching skin, limited movement of the affected part, and others. Also, the uric acid crystallizes and the crystals deposit in joints, tendons and adjacent tissues which cause a gout attack. The human body produces uric acid when it is broken down into purines. Purines are substances that are already present naturally in the body in the form of food consumed by the humans. It is caused due to a combination of genetic factor and diet. Usually, the person consuming large amounts of meat and beer faces this disease.

Global Gout Disease Treatment Market: Growth Factors

The increase in the number of gout disease incidences and strong development of the treatment are some of the major factors driving the global gout disease treatment market. Improvised study on gout therapeutics and introduction of niche drugs are other factors boosting the growth of the global gout disease treatment market. Progressive collaboration between major companies and quick product launches are some key factors impacting the growth of the market in a positive way. On the other hand, strict regulations and patent expiry of various drugs may act key restraining factors for the global gout disease treatment market.

Global Gout Disease Treatment Market

Global Gout Disease Treatment Market: Segmentation

The global gout disease treatment market is segmented on the basis of disease therapeutics and the conditional stage. The conditional stage segment is sub-segmented as acute gout and chronic gout. The therapeutic segment is further sub-segmented as urate-lowering therapies and inflammatory. The global market is segmented on the basis of the product as colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. NSAIDs are widely used for the treatment of gout disease, while corticosteroids and colchicines are the alternative treatment for the patients who are unable to tolerate the effects of NSAIDs. Region-wise, the global market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Global Gout Disease Treatment Market: Regional Analysis

North America and Europe dominate the global gout disease treatment market mainly owing to the enhanced pharmaceutical research in this area. North America is the leading player in the gout therapeutics market due to increased geriatric population with modernized routine disorders. In addition, the U.S holds the biggest market for gout Disease Treatment, followed by Canada in North America. Furthermore, Asia is anticipated to witness high growth in the near future owing to increasing awareness among people about the disease. Japan, China, and India are expected to grow rapidly in the gout Disease Treatment market in Asia.

Global Gout Disease Treatment Market: Competitive Players

Some of the major players dominating the global gout disease treatment market are Novartis AG, AstraZeneca PLC, Polaris Group, Teijin Pharma Limited, BioCryst Pharmaceuticals, Inc., Nippon Chemiphar Co., Ltd., and JW Pharmaceutical Corporation. Other key players influencing the global market are Addex Therapeutics, Takeda Pharmaceutical Company, LG Life Sciences Ltd., Pfizer, and Merck.

Gout Disease Treatment Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1.Preface
    • 1.1.Report Description
    • 1.1.Report Scope
  • Chapter 2.Research Methodology
    • 2.1.Research Methodology
    • 2.2.Secondary Research
    • 2.3.Primary Research
    • 2.4.Models
      • 2.4.1.Company Share Analysis Model
      • 2.4.2.Revenue Based Modeling
    • 2.5.Research Limitations
  • Chapter 3.Executive Summary
    • 3.1.Global Gout Disease Treatment Market, 2016 – 2026 (USD Million)
    • 3.2.Global Gout Disease Treatment Market: Snapshot
  • Chapter 4.Gout Disease Treatment Market – Industry Analysis
    • 4.1.Introduction
    • 4.2.Market Drivers
      • 4.2.1.Driving Factor 1 Analysis
      • 4.2.2.Driving Factor 2 Analysis:
    • 4.3.Market Restraints
      • 4.3.1.Restraining Factor Analysis
    • 4.4.Market Opportunities
      • 4.4.1.Market Opportunity & Use-case Analysis
      • 4.4.2.Use – Cases for Gout Disease Treatment
    • 4.5.Porter’s Five Forces Analysis
    • 4.6.COVID 19 Impact Analysis
      • 4.6.1.1.Impact on Product Development and Technology Adoption
      • 4.6.1.2.Gap Analysis
  • Chapter 5.Investment Proposition Analysis
    • 5.1.Global Gout Disease Treatment Market Attractiveness, By Conditional Stage
    • 5.2.Global Gout Disease Treatment Market Attractiveness, By Therapeutic
    • 5.3.Global Gout Disease Treatment Market Attractiveness, By Product
    • 5.4.Global Gout Disease Treatment Market Attractiveness, By Region
  • Chapter 6.Competitive Landscape
    • 6.1.Company Market Share Analysis - 2019
      • 6.1.1.Global Gout Disease Treatment Market: Company Market Share, 2019
    • 6.2.Strategic Developments
    • 7.1.Global Gout Disease Treatment Market Overview: by Conditional Stage
      • 7.1.1.Global Gout Disease Treatment Market Revenue Share, by Conditional Stage, 2019 & 2026
    • 7.2.Global Gout Disease Treatment Market Analysis/Overview – By Conditional Stage
      • 7.2.1.Acute Gout – Overview/Analysis
      • 7.2.2.Chronic Gout – Overview/Analysis
    • 7.3.Acute Gout
      • 7.3.1.Global Gout Disease Treatment Market for Acute Gout, Revenue (USD Million) 2016 - 2026
    • 7.4.Chronic Gout
      • 7.4.1.Global Gout Disease Treatment Market for Chronic Gout, Revenue (USD Million) 2016 - 2026
    • 8.1.Global Gout Disease Treatment Market Overview: by Therapeutic
      • 8.1.1.Global Gout Disease Treatment Market Revenue Share, by Therapeutic, 2019 & 2026
    • 8.2.Global Gout Disease Treatment Market Analysis/Overview – By Therapeutic
      • 8.2.1.Urate-Lowering Therapies – Overview/Analysis
      • 8.2.2.Inflammatory – Overview/Analysis
    • 8.3.Urate-Lowering Therapies
      • 8.3.1.Global Gout Disease Treatment Market for Urate-Lowering Therapies, Revenue (USD Million) 2016 - 2026
    • 8.4.Inflammatory
      • 8.4.1.Global Gout Disease Treatment Market for Inflammatory, Revenue (USD Million) 2016 - 2026
    • 9.1.Global Gout Disease Treatment Market Overview: by Product
      • 9.1.1.Global Gout Disease Treatment Market Revenue Share, by Product, 2019 & 2026
    • 9.2.Global Gout Disease Treatment Market Analysis/Overview – By Product
      • 9.2.1.Culchicine – Overview/Analysis
      • 9.2.2.Non-steroidal Anti-Inflammatory Drugs (NSAIDs) – Overview/Analysis
      • 9.2.3.Corticosteroids – Overview/Analysis
    • 9.3.Culchicine
      • 9.3.1.Global Gout Disease Treatment Market for Culchicine, Revenue (USD Million) 2016 - 2026
    • 9.4.Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 9.4.1.Global Gout Disease Treatment Market for Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Revenue (USD Million) 2016 - 2026
    • 9.5.Corticosteroids
      • 9.5.1.Global Gout Disease Treatment Market for Corticosteroids, Revenue (USD Million) 2016 - 2026
  • Chapter 10.Gout Disease Treatment Market – Regional Analysis
    • 10.1.Global Gout Disease Treatment Market: Regional Overview
      • 10.1.1.Global Gout Disease Treatment Market Revenue Share, by Region, 2019 & 2026
      • 10.1.2.Global Gout Disease Treatment Market Revenue, by Region, 2016 – 2026 (USD Million)
    • 10.2.North America
      • 10.2.1.North America Gout Disease Treatment Market Revenue, 2016 - 2026 (USD Million)
      • 10.2.2.North America Gout Disease Treatment Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 10.2.3.North America Gout Disease Treatment Market Revenue, by Conditional Stage, 2016 – 2026
      • 10.2.4.North America Gout Disease Treatment Market Revenue, by Therapeutic, 2016 – 2026
      • 10.2.5.North America Gout Disease Treatment Market Revenue, by Product, 2016 – 2026
      • 10.2.6. U.S.
      • 10.2.7.Canada
    • 10.3.Europe
      • 10.3.1.Europe Gout Disease Treatment Market Revenue, 2016 - 2026 (USD Million)
      • 10.3.2.Europe Gout Disease Treatment Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 10.3.3.Europe Gout Disease Treatment Market Revenue, by Conditional Stage, 2016 – 2026
      • 10.3.4.Europe Gout Disease Treatment Market Revenue, by Therapeutic, 2016 – 2026
      • 10.3.5.Europe Gout Disease Treatment Market Revenue, by Product, 2016 – 2026
      • 10.3.6.Germany
      • 10.3.7.France
      • 10.3.8. U.K.
      • 10.3.9.Italy
      • 10.3.10.Spain
      • 10.3.11.Rest of Europe
    • 10.4.Asia Pacific
      • 10.4.1.Asia Pacific Gout Disease Treatment Market Revenue, 2016 - 2026 (USD Million)
      • 10.4.2.Asia Pacific Gout Disease Treatment Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 10.4.3.Asia Pacific Gout Disease Treatment Market Revenue, by Conditional Stage, 2016 – 2026
      • 10.4.4.Asia Pacific Gout Disease Treatment Market Revenue, by Therapeutic, 2016 – 2026
      • 10.4.5.Asia Pacific Gout Disease Treatment Market Revenue, by Product, 2016 – 2026
      • 10.4.6.China
      • 10.4.7.Japan
      • 10.4.8.India
      • 10.4.9.South Korea
      • 10.4.10.South-East Asia
      • 10.4.11.Rest of Asia Pacific
    • 10.5.Latin America
      • 10.5.1.Latin America Gout Disease Treatment Market Revenue, 2016 - 2026 (USD Million)
      • 10.5.2.Latin America Gout Disease Treatment Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 10.5.3.Latin America Gout Disease Treatment Market Revenue, by Conditional Stage, 2016 – 2026
      • 10.5.4.Latin America Gout Disease Treatment Market Revenue, by Therapeutic, 2016 – 2026
      • 10.5.5.Latin America Gout Disease Treatment Market Revenue, by Product, 2016 – 2026
      • 10.5.6.Brazil
      • 10.5.7.Mexico
      • 10.5.8.Rest of Latin America
    • 10.6.The Middle-East and Africa
      • 10.6.1.The Middle-East and Africa Gout Disease Treatment Market Revenue, 2016 - 2026 (USD Million)
      • 10.6.2.The Middle-East and Africa Gout Disease Treatment Market Revenue, by Country, 2016 – 2026 (USD Million)
      • 10.6.3.The Middle-East and Africa Gout Disease Treatment Market Revenue, by Conditional Stage, 2016 – 2026
      • 10.6.4.The Middle-East and Africa Gout Disease Treatment Market Revenue, by Therapeutic, 2016 – 2026
      • 10.6.5.The Middle-East and Africa Gout Disease Treatment Market Revenue, by Product, 2016 – 2026
      • 10.6.6.GCC Countries
      • 10.6.7.South Africa
      • 10.6.8.Rest of Middle-East Africa
  • Chapter 11.Company Profiles
    • 11.1.Novartis AG
      • 11.1.1.Company Overview
      • 11.1.2.Financial Overview
      • 11.1.3.Product Portfolio
      • 11.1.4.Business Strategy
      • 11.1.5.Recent Developments
    • 11.2.AstraZeneca PLC
    • 11.3.Pularis Group
    • 11.4.Teijin Pharma Limited
    • 11.5.BioCryst Pharmaceuticals Inc.
    • 11.6.Nippon Chemiphar Co. Ltd
    • 11.7.JW Pharmaceutical Corporation

Methodology


Frequently Asked Questions

Growing pharmaceutical industry across the globe is a major driving factor of the gout disease treatment market. Growing prevalence of gout disease is also likely to propel the growth of the market in the near future.

According to Zion Market Research, global demand for gout disease treatment market is expected to generate revenue of around USD 9.05 Billion by end of 2026, growing at a CAGR of around 15.8% between 2020 and 2026.

The North America Gout Disease Treatment market is projected to hold the largest share globally in the future. Growing awareness and rising technology adoption in healthcare system in the region is expected to propel the demand.

Some main participants of the Gout Disease Treatment market are Novartis AG, AstraZeneca PLC, Polaris Group, Teijin Pharma Limited, BioCryst Pharmaceuticals, Inc., Nippon Chemiphar Co., Ltd., and JW Pharmaceutical Corporation. Other key players influencing the global market are Addex Therapeutics, Takeda Pharmaceutical Company, LG Life Sciences Ltd., Pfizer, and Merck, among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social